UNSPSC 51152065: Orphenadrine hydrochloride

This classification denotes an antimuscarinic agent with the molecular formula C18H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UBY910DUXH, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but more generally known as orphenadrine hydrochloride, which bears US NIH Compound Identifier 4601. European Medicines Agency schedules Orphenadrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03547MIG.

UNSPSC 51152065 Orphenadrine hydrochloride is a Commodity code that, based on recent state and local solicitations, captures pharmaceutical products and related health-system acquisitions rather than a single drug substance in isolation. The actual procurement activity under this code spans naloxone (opioid antagonist) units, safe drug deactivation systems, and pharmacy benefit program infrastructure — work initiated by county health departments, state health and human services agencies, and public health initiatives. Issuing bodies include county governments (represented by Seminole County, Florida) and state-level health agencies (Texas Health and Human Services Commission), reflecting a mix of local public health procurement and state-level pharmacy-system contracting.

Activity is concentrated in Florida and Texas, based on two recent solicitations. Seminole County, Florida issued IFB 60459723LAS (an Invitation for Bid due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the contract carries an initial two-year term with one-year renewal option and includes FEMA funding with associated federal compliance requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 (a Request for Information, due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct pharmaceutical relationships outside traditional pharmacy benefit manager arrangements. The Texas RFI represents a market-intelligence phase preceding formal competitive solicitation and does not yet commit to specific contract values or timelines.